{"classes":[{"categories":[{"measurements":[{"comment":"Less than half of the remaining participants died (more than half are still alive) after reaching the median survival.","groupId":"OG000","lowerLimit":"18.4","upperLimit":"NA","value":"31.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"From date of initial registration to date of death due to any cause. Participants last known to be alive are censored at date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"NEOADJUVANT: Patients receive atezolizumab IV over 30-60 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Cycles repeats every 21 days for 4 cycles in the absence of disease progression or unexpected toxicity.\n\nSURGERY: Within 21-90 days after completion of neoadjuvant therapy, patients undergo extrapleural pneumonectomy (EPP) or pleurectomy/decortication (PD). Patients who undergo EPP will then undergo radiation therapy.\n\nMAINTENANCE: Within 90 days after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity.","id":"OG000","title":"Treatment (Chemotherapy, Surgery +/- RT, Maintenance)"}],"paramType":"MEDIAN","populationDescription":"Eligible and evaluable participants.","reportingStatus":"POSTED","timeFrame":"3 years after the last accrual","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}